Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Oncology

Advertisement

Advertisement

Featured

Expert Roundtable
Videos
New and Upcoming Therapies for Patients With Acute Myeloid Leukemia
11/15/2024
In part 5 of this expert roundtable series, Jorge Cortes, MD, provides insight into new and upcoming therapies for treating patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 5 of this expert roundtable series, Jorge Cortes, MD, provides insight into new and upcoming therapies for treating patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 5 of this expert...
11/15/2024
Oncology
Expert Roundtable
Videos
Approaches to Treating Special Populations of Patients With Acute Myeloid Leukemia
11/15/2024
In part 4 of this expert roundtable series, Jorge Cortes, MD, provides insight into the latest updates in treating special populations of patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 4 of this expert roundtable series, Jorge Cortes, MD, provides insight into the latest updates in treating special populations of patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 4 of this expert...
11/15/2024
Oncology
Expert Roundtable
Videos
Strategies for Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
11/15/2024
In part 3 of this expert roundtable series, Jorge Cortes, MD, provides insight into strategies for treating patients with relapsed/refractory acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 3 of this expert roundtable series, Jorge Cortes, MD, provides insight into strategies for treating patients with relapsed/refractory acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 3 of this expert...
11/15/2024
Oncology
Expert Roundtable
Videos
Selecting Optimal First-Line Therapies for Patients With Acute Myeloid Leukemia
11/07/2024
In part 2 of this expert roundtable series, Jorge Cortes, MD, provides insight into optimizing frontline therapies for patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 2 of this expert roundtable series, Jorge Cortes, MD, provides insight into optimizing frontline therapies for patients with acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 2 of this expert...
11/07/2024
Oncology
Expert Roundtable
Videos
Diagnosis and Risk Stratification of Acute Myeloid Leukemia
11/07/2024
In part 1 of this expert roundtable series, Jorge Cortes, MD, provides insight into the diagnosis and risk stratification acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 1 of this expert roundtable series, Jorge Cortes, MD, provides insight into the diagnosis and risk stratification acute myeloid leukemia with Justin M Watts, MD, and Rami S Komrokji, MD.
In part 1 of this expert...
11/07/2024
Oncology
John Leonard, MD
Videos
Highlights in Novel Therapies for Lymphomas From the LL&M Congress
11/05/2024
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses novel therapies for lymphomas with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 5 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Hodgkin Lymphoma From the LL&M Congress
11/05/2024
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in Hodgkin lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 4 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Diffuse Large B-Cell Lymphoma From the LL&M Congress
11/05/2024
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in diffuse large B-cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 3 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
John Leonard, MD
Videos
Highlights in Mantle Cell Lymphoma From the LL&M Congress
11/05/2024
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert roundtable covering updates in lymphoma from the 2024 LL&M Congress, John Leonard, MD, discusses research in mantle cell lymphoma with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
In part 2 of this expert...
11/05/2024
Lymphoma, Leukemia & Myeloma Network
From Lymphoma, Leukemia & Myeloma Network
Jonathan Riess, MD
Conference Coverage
IO102-IO103 Plus Pembrolizumab Demonstrates Potential for Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
10/31/2024
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses...
10/31/2024
Oncology
Elisabeth Livingstone, MD
Conference Coverage
Early Switch From Targeted to Immunotherapy for Patients With Advanced BRAF V600-Positive Melanoma
10/31/2024
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD,...
10/31/2024
Oncology

Advertisement

Advertisement

Advertisement

https://www.hmpgloballearningnetwork.com/site/onc-app

Insights From the ESMO Congress

Jonathan Riess, MD
Conference Coverage
IO102-IO103 Plus Pembrolizumab Demonstrates Potential for Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
10/31/2024
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses phase 2 study results which demonstrated that IO102-IO103 plus pembrolizumab shows clinical promise as a first-line treatment option for patients with advanced squamous cell carcinoma of the head and neck.
Jonathan Riess, MD, discusses...
10/31/2024
Oncology
Elisabeth Livingstone, MD
Conference Coverage
Early Switch From Targeted to Immunotherapy for Patients With Advanced BRAF V600-Positive Melanoma
10/31/2024
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD, discusses results from the phase 2 ImmunoCobiVem trial which evaluated an early switch from targeted therapy to immunotherapy for patients with advanced BRAF V600-positive melanoma.
Elisabeth Livingstone, MD,...
10/31/2024
Oncology
Andrea Botticelli, MD
Conference Coverage
Using Comprehensive Genome Profiling to Guide Treatment for Patients With Metastatic Solid Tumors
10/31/2024
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD, discusses final results from the phase 2 ROME trial which demonstrated that using comprehensive genome profiling to guide treatment can improve response and survival among pretreated patients with metastatic solid...
Andrea Botticelli, MD, PhD,...
10/31/2024
Oncology
Sung Gwe Ahn, MD, PhD
Conference Coverage
Addition of Ovarian Function Suppression to Antihormonal Therapy Demonstrates Promise in HR-Positive, HER2-Positive Early Breast Cancer
10/31/2024
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses exploratory analysis results from the HERA trial which demonstrated that the addition of ovarian function suppression to antihormonal therapy shows promise in patients with HR-positive, HER2-positive early...
Sung Gwe Ahn, MD, PhD, discusses...
10/31/2024
Oncology
Giuseppe Viale, MD
Conference Coverage
Assessing HER2-Low/-Ultralow Status Could Change Treatment Landscape for Patients With HR-Positive Metastatic Breast Cancer
10/29/2024
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses...
10/29/2024
Oncology
Conference Coverage
Using TIL Score to Predict Overall Survival, Guide Trastuzumab De-Escalation Among Patients With HER2-Negative Early Breast Cancer
10/23/2024
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early...
According to results from the...
10/23/2024
Oncology
Andrea Necchi, MD
Conference Coverage
TAR-200 Plus Cetrelimab Provides Promising Clinical Benefit for Patients With Muscle-Invasive Bladder Cancer
10/23/2024
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses results from the SunRISe-4 study which assessed the addition of TAR-200 to neoadjuvant cetrelimab in a cohort of patients with muscle-invasive bladder cancer who either refused or were ineligible for...
Andrea Necchi, MD, discusses...
10/23/2024
Oncology
Conference Coverage
Addition of Durvalumab and Oleclumab to Standard SBRT and Neoadjuvant Chemotherapy Shows Clinical Promise Among Patients With ER-Positive, HER2-Negative Early Breast Cancer
10/23/2024
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the phase 2 Neo-CheckRay trial, the addition of durvalumab and oleclumab to standard SBRT and neoadjuvant chemotherapy demonstrates promise among patients with ER-positive, HER2-negative, high-risk early breast...
According to results from the...
10/23/2024
Oncology
Alberto Montero, MD, UH Seidman Cancer Center
Videos
STX-478 Demonstrates Promise in Heavily Pre-Treated Patients With PI3Kα-Mutated Solid Tumors
10/17/2024
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Georgina V. Long, MD, PhD
Conference Coverage
Adjuvant Nivolumab Sustains Clinical Benefit for Patients With Resected Stage IIB/IIC Melanoma
10/07/2024
Georgina Long, MD, PhD, discusses 3-year follow-up results from the phase 3 CheckMate 76K trial which demonstrated that adjuvant nivolumab continued to sustain clinical benefit among patients with resected stage IIB/IIC melanoma.
Georgina Long, MD, PhD, discusses 3-year follow-up results from the phase 3 CheckMate 76K trial which demonstrated that adjuvant nivolumab continued to sustain clinical benefit among patients with resected stage IIB/IIC melanoma.
Georgina Long, MD, PhD,...
10/07/2024
Oncology

Insights From the ASCO Annual Meeting

Rene Adam, MD, PhD
Conference Coverage
Chemotherapy and Liver Transplantation for Patients With Unresectable Colorectal Liver Metastases
08/02/2024
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses results from the TRANSMET trial which demonstrated that liver transplantation combined with chemotherapy significantly improved survival among patients with unresectable colorectal liver metastases.
Rene Adam, MD, PhD, discusses...
08/02/2024
Oncology
Paula Rodríguez-Otero, MD
Videos
Daratumumab Plus Bortezomib, Lenalidomide and Dexamethasone for Transplant-Eligible Patients With Newly Diagnosed MM
07/27/2024
Paula Rodríguez-Otero, MD, highlights results supporting the use of daratumumab plus bortezomib, lenalidomide and dexamethasone as a standard of care treatment for transplant-eligible patients with newly diagnosed multiple myeloma.
Paula Rodríguez-Otero, MD, highlights results supporting the use of daratumumab plus bortezomib, lenalidomide and dexamethasone as a standard of care treatment for transplant-eligible patients with newly diagnosed multiple myeloma.
Paula Rodríguez-Otero, MD,...
07/27/2024
Oncology
Paolo Ascierto, MD
Conference Coverage
Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma
07/22/2024
Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.
Paolo Ascierto, MD, discusses primary results from the phase 2 NEO-TIM trial which assessed the best sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with high-risk melanoma.
Paolo Ascierto, MD, discusses...
07/22/2024
Oncology
David Spigel, MD
Conference Coverage
Durvalumab as Standard-of-Care Consolidation Treatment for Patients With Limited-Stage Small-Cell Lung Cancer
07/19/2024
David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
David Spigel, MD, discusses the results from phase 3 ADRIATIC trial, evaluating durvalumab with or without tremelimumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
David Spigel, MD, discusses the...
07/19/2024
Oncology
Anthony El-Khoueiry, MD
Conference Coverage
Regorafenib Plus Pembrolizumab Among Patients With Advanced Hepatocellular Carcinoma Previously Exposed to Immunotherapy
07/18/2024
Anthony El-Khoueiry, MD, describes data on the combination of pembrolizumab and regorafenib showed modest activity among patients with advanced hepatocellular carcinoma who had progressed on at least 1 prior immune checkpoint inhibitor...
Anthony El-Khoueiry, MD, describes data on the combination of pembrolizumab and regorafenib showed modest activity among patients with advanced hepatocellular carcinoma who had progressed on at least 1 prior immune checkpoint inhibitor...
Anthony El-Khoueiry, MD,...
07/18/2024
Oncology
News
Thermal Ablation Over Surgical Resection for Patients With Smaller Colorectal Liver Metastases
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
IO Learning
Salomon Manier, MD, PhD
Conference Coverage
Teclistamab Plus Daratumumab and Lenalidomide Show Manageable Safety, Early Efficacy as Frontline Therapy for Patients With Transplant-Ineligible MM  
07/02/2024
At the 2024 ASCO Annual Meeting, Salomon Manier, MD, PhD, discusses data on teclistamab in combination with daratumumab and lenalidomide (DR) vs DR and dexamethasone as frontline therapy for patients with MM ineligible for transplant.
At the 2024 ASCO Annual Meeting, Salomon Manier, MD, PhD, discusses data on teclistamab in combination with daratumumab and lenalidomide (DR) vs DR and dexamethasone as frontline therapy for patients with MM ineligible for transplant.
At the 2024 ASCO Annual Meeting,...
07/02/2024
Oncology
Peter Galle, MD, PhD
Conference Coverage
Nivolumab Plus Ipilimumab As Potential New Frontline Option for Patients With Unresectable Hepatocellular Carcinoma
07/02/2024
Peter Galle, MD, PhD, discussed results from the CheckMate 9DW trial which identified nivolumab plus ipilimumab as a potential new first-line option for patients with previously untreated, unresectable hepatocellular carcinoma.
Peter Galle, MD, PhD, discussed results from the CheckMate 9DW trial which identified nivolumab plus ipilimumab as a potential new first-line option for patients with previously untreated, unresectable hepatocellular carcinoma.
Peter Galle, MD, PhD, discussed...
07/02/2024
Oncology
Andrea Cercek, MD
Conference Coverage
Neoadjuvant Dostarlimab for Patients With Locally Advanced Mismatch Repair Deficient Rectal Cancer
07/01/2024
Andrea Cercek, MD, discussed results from a phase 2 study which demonstrated durable recurrence-free with neoadjuvant dostarlimab among patients with locally advanced mismatch repair deficient rectal cancer.
Andrea Cercek, MD, discussed results from a phase 2 study which demonstrated durable recurrence-free with neoadjuvant dostarlimab among patients with locally advanced mismatch repair deficient rectal cancer.
Andrea Cercek, MD, discussed...
07/01/2024
Oncology
Efrat Dotan, MD
Conference Coverage
Gemcitabine and Nab-Paclitaxel vs 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Metastatic Pancreatic Ductal Adenocarcinoma
06/28/2024
Efrat Dotan, MD, discussed results from the phase 2 GIANT study which compared gemcitabine and nab-paclitaxel to 5-fluorouracil, leucovorin, and liposomal irinotecan among older adults with treatment-naive metastatic pancreatic cancer.
Efrat Dotan, MD, discussed results from the phase 2 GIANT study which compared gemcitabine and nab-paclitaxel to 5-fluorouracil, leucovorin, and liposomal irinotecan among older adults with treatment-naive metastatic pancreatic cancer.
Efrat Dotan, MD, discussed...
06/28/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Live Meetings

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Pembrolizumab Plus Gemcitabine-Platinum Doublet Chemotherapy Improves Survival Regardless of Platinum Agent for Urothelial Carcinoma
11/19/2024
Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...
Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...
Subset analysis results from the...
11/19/2024
Oncology
News
Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer
11/19/2024
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.
Results from the phase 3...
11/19/2024
Oncology
News
Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer
11/19/2024
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial,...
11/19/2024
Oncology
News
Robotic Laparoscopy May Have Easier Recovery For Patients With Early-Stage, Low Risk Endometrial Cancer
11/19/2024
According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.
According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.
According to a randomized...
11/19/2024
Oncology
News
UGN-102 Chemoablation as TURBT Alternative for Patients With Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer
11/19/2024
According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...
According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...
According to results from the...
11/19/2024
Oncology
News
Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer
11/18/2024
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.
According to results from a...
11/18/2024
Oncology
News
FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation
11/17/2024
On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.
On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.
On November 15, 2024, the FDA...
11/17/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement